



Quidel to Present at Pacific Growth Equities 2006 Life Sciences Growth Conference on June 13

June 6, 2006

SAN DIEGO--(BUSINESS WIRE)--June 6, 2006--Quidel Corporation (NASDAQ:QDEL), a leading provider of point-of-care (POC) rapid diagnostic tests, today announced that it will present at the Pacific Growth Equities 2006 Life Sciences Growth Conference to be held June 12-14, 2006 at the InterContinental Mark Hopkins Hotel in San Francisco.

Paul E. Landers, Quidel's senior vice president and chief financial officer, is scheduled to speak on Tuesday, June 13, 2006, at 10:00 a.m. Pacific time (1:00 p.m. Eastern time) and will discuss the Company's strategic initiatives, business developments and market opportunities. A copy of management's slide presentation will be posted on the Quidel Web site (www.quidel.com) at that time.

About Quidel

Quidel Corporation serves to enhance the health and well being of people around the globe through the discovery, development, manufacturing and marketing of rapid diagnostic solutions at the point of care (POC) in infectious diseases and reproductive health. Marketed under the leading brand name of QuickVue(R), Quidel's portfolio of products currently includes tests that aid in the diagnosis of several disease or condition states, including influenza, Strep A, pregnancy, bacterial vaginosis, infectious mononucleosis, H. pylori and Chlamydia. Quidel's products are sold to healthcare professionals with a focus on the physician office lab and acute care markets through leading medical distribution partners on a worldwide basis. Quidel's Specialty Products Group (SPG) develops research products in the fields of oncology and bone health with potential point-of-care applications in the future. By building value in rapid diagnostic tests, Quidel provides leadership to the industry and among healthcare professionals allowing for the movement of patient testing out of the central laboratory setting and into the physician office, urgent care and other outpatient settings where rapid testing and treatment has an impact on clinical outcomes and provides an economic benefit. For more information, visit www.quidel.com or www.flutest.com.

CONTACT: Quidel Corporation
Paul E. Landers, 858-552-7962
or
Lippert/Heilshorn & Associates
Don Markley/Bruce Voss, 310-691-7100

SOURCE: Quidel Corporation